iRhythm Reports Q3 Revenue Below Consensus, Delays Zio MCT FDA Submission
iRhythm reported third-quarter 2026 revenue of $221.6 million, below analyst consensus, and said Zio AT sales were flat year over year. The company delayed its next-generation Zio MCT FDA submission until 2027, citing portfolio integration challenges after its VitalConnect acquisition. Shares fell following the disclosures.
Following the release of its third-quarter 2026 financial results, iRhythm Technologies, Inc. is facing a potential securities investigation. The company reported revenue of $221.6 million, which fell short of analyst consensus, and noted that Zio AT sales were flat year-over-year. Management also disclosed that the FDA submission for its next-generation Zio MCT device has been delayed until 2027.
The company attributed both the sales slowdown and the regulatory delay to portfolio integration challenges following its acquisition of VitalConnect. Shares of the company experienced a significant decline following these disclosures.